A groundbreaking study from Università Cattolica in Rome and Roma Tre University has identified a key protein, PP2A-B55α (also known as PPP2R2A), as a critical regulator of mitochondrial homeostasis, essentially the balance between clearing out damaged mitochondria and generating new ones. This discovery could open new doors for treating Parkinson’s Disease and other mitochondrial disorders.
What Is PP2A-B55α?
PP2A-B55α is a part of a protein team that helps control how other proteins work by removing tiny chemical tags called phosphate groups. These tags can turn proteins “on” or “off.” While scientists already know a lot about proteins that add these tags (called kinases), they have not understood much about the ones that remove them, like PP2A-B55α. This new research shows that PP2A-B55α plays a big role in keeping mitochondria healthy, especially in diseases like Parkinson’s.
Dual Role in Mitochondrial Turnover
Scientists discovered that this protein helps keep our cells’ energy centers, the mitochondria, healthy in two important ways:
- First, it helps clean up damaged mitochondria through a process called mitophagy (think of it like taking out the trash).
- Secondly, it slows down the creation of new mitochondria when everything is working normally, so the cell doesn’t make more than it needs.
What is really interesting is that this protein works at two different times during the cleanup process. Early on, it turns on a signal that tells the cell, “Hey, this mitochondrion is broken, get rid of it!” Then, later, it helps activate genes that keep the cleanup going strong.
So, PP2A-B55α acts like a manager, making sure damaged mitochondria are removed properly and that new ones are only created when necessary. This balance is especially important in diseases like Parkinson’s, where damaged mitochondria can cause serious issues.
Implications for Parkinson’s Disease
Researchers tested their findings using fruit fly models. When they lowered the levels of PP2A-B55α, the flies showed better movement and healthier mitochondria. But this only worked when another protein called Parkin was present. Parkin is already known to help clean up damaged mitochondria.
The study also found that PP2A-B55α affects how new mitochondria are made. It does this by keeping a protein called PARIS stable, which normally blocks another protein (PGC-1α) that helps make new mitochondria. So, when PP2A-B55α is reduced, PARIS becomes less active, and PGC-1α can do its job, leading to more healthy mitochondria being produced.
Beyond Parkinson’s: A Broader Therapeutic Potential
The implications go beyond Parkinson’s. Since mitochondrial dysfunction is a hallmark of several diseases, including mitochondrial myopathies, Duchenne muscular dystrophy, and even certain cancers, targeting PP2A-B55α could become a promising therapeutic strategy.
The research team is now focused on identifying small molecules that can safely and selectively modulate PP2A-B55α in neurons. This could pave the way for targeted treatments for a range of mitochondrial-related diseases, many of which currently lack effective therapies.